TMCnet News
AHF: Gilead Outrage on Hep C Drug Price!WASHINGTON --(Business Wire)-- AIDS Healthcare Foundation (AHF), the nation's largest HIV/AIDS nonprofit medical provider, expressed its profound outrage at Gilead Sciences over the price of Sovaldi, its new Hepatitis C drug, which was approved by the Food and Drug Administration (FDA) on Friday. Gilead set the price at $84,000 Wholesale Acquisition Cost (WAC (News - Alert)) for a twelve-week supply of the drug--$1,000 per pill. The drug, known during drug trials as GS-7977 (sofosbuvir), is one component of a two-drug, twelve-week combination treatment for Hepatitis C, which affects an estimated 3.2 million people in the United States. >
MEDIA AVAILABILITY: AHF to comment on FDA approval, and Gilead's pricing, of its new Hepatitis C drug, Sovaldi (sofosbuvir). WHO: Michael Weinstein, President, AIDS Healthcare Foundation CONTACT: Ged Kenslea, AHF Communications +1.323.791.5526 mobile AIDS Healthcare Foundation (AHF), the largest global AIDS organization, currently provides medical care and/or services to more than 260,000 individuals in 32 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Eastern Europe. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook (News - Alert): www.facebook.com/aidshealth and follow us on Twitter (News - Alert): @aidshealthcare
|